Amgen’s Higher Yield Faces Gilead’s Lower Payout and Valuation
Amgen offers the higher forward yield and stronger recent product sales growth, while Gilead Sciences has a lower payout ratio and forward earnings multiple. The comparison also turns on each drugmaker’s pipeline and the type of income investor weighing the stocks, according to Yahoo Finance.
Amgen has the higher forward dividend yield, while Gilead Sciences scores better on payout ratio and valuation, according to a Yahoo Finance comparison of the two biotech stocks. The figures leave income investors weighing current yield against the share of earnings paid out and each company’s drug pipeline.
Amgen’s forward dividend yield tops 2.2%, compared with Gilead Sciences’ yield of slightly below 2.1%. Gilead, however, has a dividend payout ratio of 43.5%, lower than Amgen’s 60.9%, and trades at 15.6 times forward earnings against Amgen’s 16.7.
The comparison does not point to a single clear winner. Yahoo Finance says the choice depends on whether investors prioritize yield and growth, dividend safety or valuation.
Amgen leads on yield and recent sales growth
Amgen’s product sales increased by 9% year over year in its latest quarter, the source reported. Gilead Sciences posted 8% growth over the same comparison period.
The companies also differ in the breadth of their current product lineups. Amgen has 17 drugs on track to be blockbusters this year, compared with eight for Gilead Sciences. The source describes Amgen’s lineup as arguably slightly stronger, while noting that the companies’ pipelines make the longer-term comparison less straightforward.
Pipeline numbers tell a mixed story. Amgen has 44 programs, including 29 in late-stage development. Gilead says it has 53 clinical-stage programs, but 15 are in Phase 3 clinical studies.
That distinction matters to the dividend comparison because future products may shape how each company sustains its business, though the source notes there is no single online metric that establishes which company is better positioned to keep paying dividends. Investors have to consider product lineups, competition and pipeline programs.
Gilead has the edge on payout ratio and valuation
Gilead’s lower payout ratio means it distributes a smaller share of earnings as dividends than Amgen does, based on the figures in the Yahoo Finance analysis. The article says lower payout ratios are generally preferable when comparing dividend stocks.
Its valuation also comes in lower: Gilead trades at 15.6 times forward earnings, while Amgen trades at 16.7 times. Those measures favor Gilead for investors focused on value, even as Amgen holds the advantage on yield and the latest reported product sales growth.
For income investors seeking yield and growth, the Yahoo Finance analysis favors Amgen, citing its higher yield, product lineup and late-stage pipeline. Investors who put greater weight on payout safety or valuation may prefer Gilead. The article also says some investors may choose to own both, noting that each offers a higher dividend yield than the S&P 500 and what it describes as more attractive valuations.
The comparison is based on the figures and company pipeline descriptions reported; it does not establish a guaranteed dividend or investment outcome. The source’s conclusion is conditional on investors’ priorities, with the companies’ product development programs remaining part of the assessment.
